Autolus Therapeutics and Taysha Gene Therapies occupy different corners of the biotechnology sector, yet both have drawn intense investor attention in recent market activity. This stock comparison is relevant for investors weighing a commercial-stage cell therapy business against a pre-revenue gene therapy developer. AUTL is executing a U.S. product launch, while TSHA is advancing toward a potential regulatory filing. Comparing their relative performance, business models, and market positioning can help traders and longer-term investors assess where momentum, stability, and catalyst risk currently reside in the small-cap biotech space.
Autolus Therapeutics is a commercial-stage biopharmaceutical company developing programmed T-cell therapies for cancer and autoimmune diseases. Its lead product, Aucatzyl (obecabtagene autoleucel, or obe-cel), is an approved CAR-T therapy for adult relapsed/refractory B-cell acute lymphoblastic leukemia. In recent weeks, the company has emphasized commercial execution, reporting strong quarter-over-quarter revenue growth and a shift to positive gross margin as manufacturing costs improved. Management also raised full-year product revenue guidance, reflecting an expanding treatment-center footprint. Despite this operational progress, the stock has declined meaningfully over the trailing 30 days, with sentiment pressured by broader biotech volatility and questions about the pace and profitability of cell therapy commercialization. Near-term catalysts include longer-term autoimmune data and continued launch momentum.
Taysha Gene Therapies is a clinical-stage biotechnology company focused on AAV (adeno-associated virus)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead candidate, TSHA-102, is in pivotal development for Rett syndrome and has received regulatory designations designed to expedite review. Recent market activity has centered on advancing the REVEAL pivotal trial, alignment with regulators on a potential BLA submission, and an expanded manufacturing agreement. The company has reported favorable safety data and clinical progress, which has supported analyst confidence. Nevertheless, TSHA shares have also declined over the past month, and the stock remains highly sensitive to binary clinical and regulatory events given the absence of meaningful revenue. Its catalyst path depends largely on trial readouts and the timing of a potential filing.
Tickeron operates hundreds of AI trading bots that trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance record, and universe of securities. Because market conditions change, not every bot is suited to the current environment. The Trending AI Robots section curates only the strategies that Tickeron's platform currently identifies as best aligned with prevailing conditions, offering traders a filtered view rather than an overwhelming list. These bots vary in approach, from short-term momentum to longer-horizon trend following, and their published statistics let users compare performance and risk profiles side by side. For investors tracking names like AUTL and TSHA, reviewing this curated selection can provide an additional, data-driven perspective on positioning.
The clearest contrast between these two companies is stage of development. AUTL has an approved product, real revenue, and a defined path toward gross-margin expansion, making its fundamentals more visible but also exposing it to execution and reimbursement risk. TSHA is pre-revenue, with its valuation tied almost entirely to TSHA-102 clinical and regulatory outcomes, creating a binary, catalyst-driven risk profile. On growth drivers, AUTL depends on expanding physician adoption and new autoimmune indications, while TSHA depends on Rett syndrome data durability and a successful filing. In terms of recent momentum, both have pulled back, but TSHA carries a larger market capitalization and a wider spread between its price and analyst targets, reflecting higher embedded expectations. Sector exposure differs subtly: AUTL sits in oncology and cell therapy, while TSHA is anchored in rare-disease gene therapy. Overall, AUTL offers comparatively greater stability and visible revenue, whereas TSHA offers a higher-risk, higher-uncertainty catalyst profile.
Based on observable factors, Tickeron's AI would likely favor AUTL at this juncture. The company's combination of growing product revenue, positive gross margin, raised guidance, and a commercial foundation offers a more consistent trend and a less binary risk profile than TSHA, whose outlook rests heavily on single clinical and regulatory events. That said, this is a probabilistic assessment rather than a definitive outcome: TSHA's larger potential catalysts could shift relative positioning quickly if pivotal data and regulatory milestones land favorably. Investors should weigh AUTL's stability against TSHA's higher-uncertainty, higher-upside profile.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 50-day moving average for AUTL moved below the 200-day moving average on November 17, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Moving Average Convergence Divergence Histogram (MACD) for AUTL turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 33 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUTL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for AUTL entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where AUTL advanced for three days, in 224 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
AUTL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.552) is normal, around the industry mean (3.596). P/E Ratio (-1.208) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (4.228) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. AUTL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUTL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
TSHA saw its Momentum Indicator move below the 0 level on November 17, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned negative. In 76 of the 83 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for TSHA turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 42 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TSHA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TSHA's RSI Oscillator exited the oversold zone, 31 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where TSHA advanced for three days, in 213 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
TSHA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 123 of 155 cases where TSHA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.643) is normal, around the industry mean (3.596). P/E Ratio (-10.561) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (333.333) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. TSHA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TSHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
AUTL | TSHA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 53 | 56 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 71 Overvalued | 21 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 98 | |
PRICE GROWTH RATING 1..100 | 88 | 75 | |
P/E GROWTH RATING 1..100 | 35 | 22 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TSHA's Valuation (21) in the null industry is somewhat better than the same rating for AUTL (71) in the Biotechnology industry. This means that TSHA’s stock grew somewhat faster than AUTL’s over the last 12 months.
TSHA's Profit vs Risk Rating (100) in the null industry is in the same range as AUTL (100) in the Biotechnology industry. This means that TSHA’s stock grew similarly to AUTL’s over the last 12 months.
TSHA's SMR Rating (98) in the null industry is in the same range as AUTL (99) in the Biotechnology industry. This means that TSHA’s stock grew similarly to AUTL’s over the last 12 months.
TSHA's Price Growth Rating (75) in the null industry is in the same range as AUTL (88) in the Biotechnology industry. This means that TSHA’s stock grew similarly to AUTL’s over the last 12 months.
TSHA's P/E Growth Rating (22) in the null industry is in the same range as AUTL (35) in the Biotechnology industry. This means that TSHA’s stock grew similarly to AUTL’s over the last 12 months.
| AUTL | TSHA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | 4 days ago 89% |
| Stochastic ODDS (%) | 2 days ago 89% | 2 days ago 79% |
| Momentum ODDS (%) | N/A | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 87% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 88% |
| Advances ODDS (%) | 13 days ago 86% | 13 days ago 82% |
| Declines ODDS (%) | 2 days ago 88% | 2 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 84% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 79% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AUTL’s FA Score shows that 0 FA rating(s) are green while TSHA’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AUTL’s TA Score shows that 4 TA indicator(s) are bullish while TSHA’s TA Score has 5 bullish TA indicator(s).
AUTL (@Biotechnology) experienced а -22.45% price change this week, while TSHA (@Biotechnology) price change was -9.27% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.
AUTL is expected to report earnings on Mar 10, 2027.
TSHA is expected to report earnings on Mar 03, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, AUTL has been loosely correlated with CRSP. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AUTL jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To AUTL | 1D Price Change % | ||
|---|---|---|---|---|
| AUTL | 100% | -7.38% | ||
| CRSP - AUTL | 46% Loosely correlated | +0.44% | ||
| SANA - AUTL | 43% Loosely correlated | -8.62% | ||
| EDIT - AUTL | 43% Loosely correlated | -4.09% | ||
| RCKT - AUTL | 43% Loosely correlated | -7.58% | ||
| TSHA - AUTL | 43% Loosely correlated | -1.33% | ||
More | ||||
A.I.dvisor indicates that over the last year, TSHA has been loosely correlated with SLDB. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if TSHA jumps, then SLDB could also see price increases.
| Ticker / NAME | Correlation To TSHA | 1D Price Change % | ||
|---|---|---|---|---|
| TSHA | 100% | -1.33% | ||
| SLDB - TSHA | 52% Loosely correlated | -2.95% | ||
| STOK - TSHA | 51% Loosely correlated | -0.45% | ||
| BNTC - TSHA | 51% Loosely correlated | -2.76% | ||
| MGTX - TSHA | 50% Loosely correlated | -1.97% | ||
| NGNE - TSHA | 49% Loosely correlated | -3.40% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MLPB | 27.16 | -0.48 | -1.73% |
| ETRACS Alerian MLP Infrastructure Index ETN Series B (MLPB) | |||
| DDTM | 19.53 | -0.46 | -2.31% |
| Innovator Equity Dual Directional 10 Buffer ETF - March (DDTM) | |||
| VGK | 82.61 | -1.96 | -2.32% |
| Vanguard FTSE Europe ETF (VGK) | |||
| THQ | 17.12 | -0.55 | -3.11% |
| abrdn Healthcare Opportunities Fund | |||
| ABIG | 31.73 | -1.21 | -3.67% |
| Argent Large Cap ETF (ABIG) | |||